‘Alpha-1 Antitrypsin Deficiency (AATD) Financial Cost’ provides an in-depth analysis of the financial burdens associated with Alpha-1 Antitrypsin Deficiency (AATD), referencing 14 unique research studies. These studies cover various aspects of medical expenses, including augmentation therapy, hospitalization, emergency care, outpatient care, and the long-term financial impact on patients and families. The book offers valuable insights into the economic challenges faced by AATD patients and their families, helping them make informed decisions about treatment options, insurance coverage, and resource allocation.
The book contributes to the development of healthcare strategies by highlighting the cost-effectiveness of various treatment options and identifying areas where financial support is needed. It brings innovative ideas and research by examining emerging treatments, such as gene therapy and small molecule therapies, and their economic impact. Additionally, the book offers strategies for reducing healthcare costs and improving the overall quality of life for AATD patients. This comprehensive approach makes it a valuable resource for anyone interested in the financial aspects of healthcare and the management of Alpha-1 Antitrypsin Deficiency.
Circa l’autore
I am bestselling author. I have proven technical skills (Google certifications) to deliver insightful books with ten years of business experience. I have written and published 400 books as per Goodreads record.
ORCID: https://orcid.org/0009-0004-8629-830X
[email protected]
Altri ebook dello stesso autore / Editore
145.635 Ebook in questa categoria
